NCT00349739

Brief Summary

The purpose of this study is to evaluate whether anecortave acetate can slow or stop the progression of age-related macular degeneration in patients who do not qualify for other studies and have no other treatment options.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2003

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2003

Completed
3.5 years until next milestone

First Submitted

Initial submission to the registry

July 6, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

July 10, 2006

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2008

Completed
Last Updated

January 15, 2010

Status Verified

January 1, 2010

First QC Date

July 6, 2006

Last Update Submit

January 14, 2010

Conditions

Macular Degeneration

Keywords

age related macular degeneration

Interventions

Anecortave AcetateDRUG

Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days

Also known as: Retaane

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Choroidal neovascularization, mostly occult
  • Visual acuity \> 20/40 in study eye

You may not qualify if:

  • Allergy to fluorescein dye
  • Inability to stop warfarin prior to treatment
  • Pregnancy
  • Other serious ocular diseases or conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Iowa Hospitals and Clinics, Ophthalmology

Iowa City, Iowa, 52242, United States

Location

Related Links

MeSH Terms

Conditions

Macular Degeneration

Interventions

anecortave acetate

Condition Hierarchy (Ancestors)

Retinal DegenerationRetinal DiseasesEye Diseases

Study Officials

  • Edwin M Stone, MD, PhD

    University of Iowa

    PRINCIPAL INVESTIGATOR

  • Stephen R. Russell, MD

    University of Iowa

    STUDY DIRECTOR

Study Design

Study Type
expanded access
Sponsor Type
OTHER

Study Record Dates

First Submitted

July 6, 2006

First Posted

July 10, 2006

Study Start

January 1, 2003

Study Completion

August 1, 2008

Last Updated

January 15, 2010

Record last verified: 2010-01

Locations

US(1)